Overexpression of Wild-type p53 in Lichen Sclerosus adjacent to Human Papillomavirus-negative Vulvar Cancer  by Vanin, Katrina et al.
ORIGINAL ARTICLE
Overexpression of Wild-type p53 in Lichen Sclerosus adjacent
to Human Papillomavirus-negativeVulvar Cancer
Katrina Vanin,nw James Scurry,w Heather Thorne,n KallyYuen,z and Robert G. Ramsayn
nTrescowthick Research Laboratories, Peter MacCallum Cancer Institute, Melbourne, Australia; wDepartment of Pathology, Mercy Hospital forWomen,
East Melbourne, Australia; zStatistical Center, Peter MacCallum Cancer Institute, Melbourne, Australia
Human papillomavirus is a risk factor for vulvar can-
cer, whereas human papillomavirus-negative late onset
vulvar carcinoma is associated with the dermatologic
condition, lichen sclerosus. Human papillomavirus E6
protein targets TP53 for degradation and by inference
it has been assumed that human papillomavirus-nega-
tive vulvar cancer is dependent upon the acquisition of
p53 somatic mutations and subsequent allelic loss.To in-
vestigate this, TP53 expression, loss of heterozygosity,
and p53 genomic sequence were examined in 29 cases
of human papillomavirus-negative vulvar carcinoma
with adjacent lichen sclerosus.We examined 37 cases of
lichen sclerosus without vulvar carcinoma, 10 cases of
nongenital lichen sclerosus, and 12 cases of normal vul-
var epithelium served as controls. TP53 was evident in
72% of vulvar carcinoma, 48% in epithelium adjacent
to vulvar carcinoma, but was minimal in normal sam-
ples. When lichen sclerosus cases were selected to ex-
clude samples with absolutely no TP53 expression
through probable failed antigen retrieval or homozy-
gous p53 loss the number of epithelial cells expressing
TP53 increased progressively from nongenital lichen
sclerosus to lichen sclerosus without vulvar carcinoma,
then to lichen sclerosus with vulvar carcinoma
(po0.0001).These data suggest elevated TP53 is a feature
of vulvar lichen sclerosus. Seventy-four percent of vul-
var carcinoma had chromosome 17p-linked loss of het-
erozygosity, whereas 47% of adjacent lichen sclerosus
featured loss of heterozygosity, but only 31% of vulvar
carcinoma had p53 mutations, a frequency less than re-
ported previously. Seven percent of adjacent lichen
sclerosus had mutations, showing for the ¢rst time the
presence of an identical mutation to the matched vulvar
carcinoma. These data, however, implicate p53 muta-
tions as a later event in vulvar carcinoma and in marked
contrast to the original expectation, our loss of hetero-
zygosity data are consistent with loss of another locus
(not p53) on 17p operating as a tumor suppressor in
lichen sclerosus destined to develop vulvar carcinoma.
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V
ulvar squamous cell carcinoma development follows
two pathways. One strongly associated with human
papillomavirus (HPV) serotypes 16 and 18, the other
occurring over a longer time frame, in the context
of the dermatologic disease lichen sclerosus (LS).
LS documented as an adjacent epithelial lesion to vulvar carcino-
ma (VC) ranges from 9% to 100% (Leibowitch et al, 1990;Toki et
al, 1991; Hording et al, 1994; Ridley, 1994). Thus the relevance of
LS to VC is controversial. For decades it has been hypothesized
that LS is a predisposing condition to VC (Carlson et al, 1998).
Although LS can develop all over the body, it is only on the vul-
va, penis, and perineum that it is associated with cancer (Weber
et al, 1987; Pride et al, 1993; Ridley, 1994).
The HPV E6 protein functionally inactivates the tumor sup-
pressor gene protein, TP53, ablating its activity as a cell-cycle
regulator and transcriptional activator in DNA damage, repair
responses, and apoptosis (Thomas et al, 1999). Thus it has been
presumed that E6-mediated TP53 degradation obviates the selec-
tive pressure for p53 mutagenesis in HPV-positive cancers as these
tumors rarely show p53 mutations (Crook et al, 1992; Fujita et al,
1992; Helland et al, 1993; Kessis et al, 1993; Park et al, 1994). This is
also the case for VC. Previous studies have reported 22^75% of
HPV-negative VC harbor p53 mutations (Lee et al, 1994; Milde-
Langosch et al, 1995; Pilotti et al, 1995; Kim et al, 1996; Sliutz et al,
1997). These observations suggest that p53 somatic mutations
accumulate over time in HPV-negative VC similar to the general
trend in other epithelial tumors (Hollstein et al, 1991; Greenblatt et
al, 1994). It is unclear, however, whether the described precursor
lesions adjacent to HPV-negative VC arise or progress to tumors
in a p53 mutation-dependent manner.
Generally, the detection of TP53 expression is thought to be
indicative of either induced or transient stabilization of wild-type
protein, or more commonly a mutation leading to more stable
mutant TP53 (May et al, 1999). Increased TP53 expression in LS
of the vulva without VC compared with nongenital LS has been
reported suggesting that there may be an anatomical di¡erence in
the two subtypes of LS or a di¡erence in the degree of carcino-
genic stimulation (Soini et al, 1994). In this study we investigated
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the p53 status in LS as an indicator of a cellular stress response
and/or ‘‘preneoplastic’’ change.We have brought together cases of
documented HPV-negative VC with adjacent LS, LS of the vulva
without VC, nongenital LS, and normal vulvar epithelium, ex-
cluding the possibility that TP53 expression was being altered
by HPV. For the ¢rst time the status of the p53 gene was assessed
simultaneously using three criteria: immunohistochemistry, loss
of heterozygosity (LOH), and direct sequencing to investigate
molecular changes in VC and its adjacent epithelial components
in comparison with LS of the vulva in the absence of cancer and
in nongenital LS.
This systematic and comprehensive study of p53 status has
highlighted the strong expression of wild-type TP53 in LS of
the vulva but not in nongenital LS or normal vulvar epithelium.
The data support the suggestion that the overexpression of wild-
typeTP53 is an important feature of LS of the vulva distinguish-
ing it from LS elsewhere and certainly normal skin. Although
LOH and p53 mutations are frequent in VC, our data support
the view that p53 mutagenesis is involved in the later stages of
vulvar carcinogenesis. Furthermore, it is proposed that the mole-
cular changes associated with progression of VC from associated
LS uncommonly involve p53 mutation but rather our LOH data
suggest another tumor suppressor gene on chromosome 17p may
be important.
MATERIALS AND METHODS
Clinical specimens and histologic assessment Twenty-nine cases of
invasive vulvar squamous cell carcinoma and with adjacent LS. Forty-four
cases of LS of the vulvar without carcinoma collected from and diagnosed
at the Mercy Hospital for Women and Royal Women’s Hospital between
1985 and 1997 were selected. Ten cases of nongenital LS on the body
diagnosed at Dorevitch Pathology (Melbourne) were also included.
Twelve cases of normal vulvar epithelium and three cases of nongenital
normal skin collected from the Mercy Hospital for Women were used as
controls. Each VC case was identi¢ed by histologic criteria as described
previously (Scurry et al, 1997) on the basis of: (i) presence of adjacent LS;
(ii) unequivocal presence of VC; and (iii) su⁄cient archival material for
molecular and immunohistochemical analysis. Epithelial skin adjacent to
the tumor was classi¢ed as normal, LS, squamous cell hyperplasia (SCH),
di¡erentiated vulvar intraepithelial neoplasia (DVIN), or undi¡erentiated
vulvar intraepithelial neoplasia. HPV typing of a larger series of VC cases,
including the series reported here, was performed previously (Scurry et al,
1998). In this study all HPV-positive cases detected using polymerase chain
reaction (PCR) primers to genotypes 16, 18, or pan-HPVwere excluded.
Immunohistochemistry Analysis of TP53 and p21CIP-1/WAF-1 expres-
sion was carried out using mouse anti-TP53 Ab6 (Calibochem (San
Diego, CA)) and mouse anti-p21 Ab3 (Neomarkers (Fremont, CA))
antibodies following antigen retrieval. Three micrometer sections were
cut from the formalin-¢xed para⁄n-embedded tissue blocks and collected
on 3-aminopropyltriethoxy-silane (Sigma (Sydney, NSW, Australia))
treated slides. Sections were dewaxed in xylene and rehydrated in graded
methanol. Endogenous peroxidases were blocked with 0.9% H2O2/
methanol for 15 min, then hydrated. Antigen retrieval was performed
using boiling 10 mM citrate bu¡er (pH 6) incubated for 20 min in a
microwave oven at low power, and then allowed to cool. Sections were
washed twice in Tris-bu¡ered saline (TBS: 0.25 M NaCl, 25 mM Tris pH
7.6). Nonspeci¢c binding was blocked with 2% fetal bovine serum
(P.A.Biologicals (Havelock North, New Zealand))/TBS for 30 min.
Sections were incubated with the primary antibody in 2% fetal bovine
serum/TBS (1 : 50 dilution) for 60 min, washed with TBS (5 min), then
incubated with goat anti-mouse horseradish peroxidase antibody (Bio-
Rad (Hercules, CA); 1 : 200 dilution), in 2% fetal bovine serum/TBS
for 30 min. Sections were then washed with TBS (5 min). Protein
expression was visualized using 0.05% diaminobenzidine (Sigma) in TBS,
the reaction was activated with 20 ml H2O2, sections were counter-stained
with hematoxylin for 1 min, dehydrated in graded ethanol, cleared in
xylene and mounted with DPX mounting solution (BDH (Merck,
Kilsythe,Vic, Australia)) and cover-slipped.
TP53 expression was scored per 100 basal cells as described previously
(Tan et al, 1994). Brie£y, 100 consecutive basal cells were identi¢ed and all
cells above the basement membrane (epidermis) in this ¢eld were scored
for TP53 expression. Three separate ¢elds were assessed and the average
used in the determination of expression. Intensity of TP53 expression
(0¼ not detected, 1¼ light, 2¼medium, 3¼ dark) in all tissues studied.
Cases were considered negative if there was no evidence of p53 or p21
expression in the entire section. Three observers using reference slides
with agreed straining intensities reviewed all sections.
DNA extraction Sections of 5 mm were cut from the formalin-¢xed
para⁄n-embedded tissue blocks. Sections were dewaxed in xylene and
rehydrated in graded ethanol, and then stained using hematoxylin and
eosin. The VC and adjacent epithelium, vulvar LS without VC, and
nongenital LS were microdissected using a micropapillary pipette (Sigma)
attached to a micromanipulator (Nikon (Tokyo, Japan)) and visualized
through an inverted microscope (Nikon). Hematoxylin and eosin stained
sections in combination with the immunohistochemically stained sections
were used to guide microdissection.The microdissected cells were collected
in silicon-treated Eppendorf tubes. Protein was removed with Proteinase K
digestion and the DNA precipitated with isopropanol and 300 mM sodium
acetate in the presence of 20 mg of nuclease-free glycogen.
LOH These studies were performed using two p53 polymorphic markers,
a pentanucleotide Alu sequence with an (AAAAT)8 repeat (Cawkwell et al,
1994) and a dinucleotide (CA)25 repeat (Jones and Nakamura, 1992). Sense
and anti-sense primers £anking the pentanucleotide and dinucleotide loci
are as previously described (Jones and Nakamura, 1992; Cawkwell et al,
1994). PCR were performed in 25 ml containing 0.5 mm of each forward
primer (Bresatec (Adelaide, SA, Australia)) and 1.5 mm of reverse primer
end-labeled with [g-32P] adenosine triphosphate (3000 Ci per mol, 10 mCi
per ml) (Dupont (Wilmington, DE)), 200 ml deoxyribonucleoside
triphosphate (Promega (Annandale, NSW, Australia)), 2.5 mM MgCl2,
2.5 ml10 PCR Bu¡er (Perkin Elmer (Boston, MA)), 0.25 mM spermidine,
1.2 mM Taq Start Antibody (Clontech), 0.88 mlTaq Start Antibody Dilution
Bu¡er (Clontech (Palo Alto, CA)), 1U Taq polymerase and 1^3 ng DNA.
Pentanucleotide marker PCRwere performed after denaturation at 941C
for 5 min, two cycles of denaturation at 951C for 30 s, annealing at 631C to
551C, at 21C intervals for 30 s and extension at 721C for 30 s, 32 cycles,
including denaturation at 951C for 30 s, annealing at 551C for 30 s and
extension at 721C for 30 s with a ¢nal extension at 721C for 10 min.
Similarly, dinucleotide marker PCR was performed as described except
annealing was performed at 681C to 601C. Denaturing bu¡er, 8 ml (20
mM ethylenediamine tetraacetic acid, 0.05% xylene cyanol, 0.05%
bromophenol blue, and 95% formamide) was added to 5 ml of the PCR
product. Samples were heat denatured and immediately cooled on ice.
The samples were loaded on to a 6% polyacrylamide/Tris-borate-
ethylenediamine tetraacetic acid electrophoresis bu¡er gel. Upon
completion of electrophoresis the gel was dried and exposed to Kodak
Biomax-MR ¢lm overnight. LOH was scored by visual detection as a
minimum of 50% reduction in band intensity.
p53 mutation analysis Primers for p53 exons 5, 6, 7, and 8 have been
described previously (Brash et al, 1991) and PCR were performed
essentially as described above with the following modi¢cations. Exons 5
and 6 PCRwere performed at an initial denaturation of 941C for 5 min,
then 32 cycles of: denaturation at 951C for 30 s, annealing at 661C to 581C
(21C intervals for 30 s) and extension at 721C for 30 s and ¢nal extension at
721C for 10 min. Exon 8 PCR were also performed similarly except
annealing was at 581C to 501C. PCRwas performed for exon 7 following
the same program as the pentanucleotide repeat in the LOH analysis. PCR
products were analyzed on a 2% agarose gel. Primers and primer-dimers
were removed from the PCR extended products with Wizardt PCR
preps DNA puri¢cation System (Promega). Direct DNA sequencing of
ampli¢ed PCR products using an internal primer (Bresatec) speci¢c for
each exon was performed using the SequiThermt Cycle Sequencing Kit
(EpicentreTechnologies (Owens Cross Roads, AL)) and [a-33P]deoxyadenosine-
triphosphate (Dupont).
Exon 5: 50TTCCTCTTCCTGCAGTACTC 30
Exon 6: 50CAGACCTCAGGCGGCTCATA 30
Exon 7: 50GGTTGGCTCTGACTGTACCA 30
Exon 8: 50GGTTTCTTCTTTGGCTGGGG 30.
DNA sequences were analyzed on a 6% polyacrylamide/Tris-borate-
ethylenediamine tetraacetic acid electrophoresis bu¡er sequencing gel.
Autoradiography was performed overnight.
Statistical analyses To test whether TP53 expression increased from
nongenital LS to LS of the vulva without VC to LS adjacent to VC, for
each case, three microscopic ¢elds were chosen at random from the
corresponding tissue. In three cases of LS of the vulva without VC, fewer
than three ¢elds were taken due to insu⁄cient tissue. For each case, the
average of the TP53 expression scores was obtained. The hypothesis was
tested using nonparametric analysis of variance (one-sided Jonckheere^
Terpstra test). The intensity score was dichotomized to 2 or more vs less
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than 2. To test the hypothesis that the intensity increased from nongenital
LS to LS of the vulva without VC to LS adjacent to VC, a one-sided
Cochran^Armitage test for trend for ordinal data based on the exact
distribution was used. For each VC case, the intensity scores were
documented in the tumor and its adjacent epithelium, where possible. The
aim was to examine whether there was evidence for increasing TP53
intensity from the normal epithelium, to LS only, to LS coexistent with
SCH/DVIN, to the tumor. As results from the same case may be
correlated, the analysis was performed using a logistic regression model
with distinguishable binomial random e¡ect (Collett, 1991). A linear term
was included in the model indicating the ranking of the type of tissue in
terms of increasing neoplasia.The normal epitheliumwas given a rank of 1,
LS had a rank or 2, LS coexistent with SCH/DVIN had a rank of 3 and the
tumor had a rank of 4. A one-sided likelihood ratio test was used to test the
signi¢cance of this term after removing it from the model. The deviance
and the degrees of freedom associated with the model were examined for
goodness of ¢t.
A permutation test was used to determine whether the observed
matching of mutations inVC and LS of the same case was consistent with
chance. The test was carried out by considering all the possible
permutations of results for the 29 VCmutation outcomes with the 29 muta-
tion outcomes of LS.The p-value was the proportion of these permutations
for which at least the observed number of matching mutations occurred.
All tests carried out, unless speci¢ed, were two-sided, and po0.05 was
considered to be signi¢cant. No formal adjustments were made for
multiple comparisons. The analyses were carried out using StatXact for
Windows (version 4.0) and EGRET statistical package for Windows
(version 2.0.1).
RESULTS
TP53 expression Twenty-nine tumor samples were classi¢ed
into three groups: (i) tumor and adjacent components exhibiting
TP53 expression (14 cases); (ii) expression restricted only to the
tumor (seven cases); and (iii) tumor and adjacent components
TP53 negative (eight cases). TP53 expression in the adjacent
epithelium was largely localized to focal patches or clusters of
epithelial cells mainly con¢ned to basal and parabasal layers and
thus indicative of clonal heterogeneity (Fig 1A, panels 1 and 2).
This compares with extensive TP53 staining in VC (Fig 1A,
panel 3). Four of 14 VC cases had TP53 expression in apparently
normal adjacent epithelium.
Sparse and weak TP53 basal expression was mainly seen in 37
of 44 LS of the vulvar without carcinoma specimens (Fig 1A,
panel 4), whereas the nongenital LS cases, on average, had weaker
expression (Fig 1A, panel 5). One LS case of the vulvar without
carcinoma had markedly intense and extensive TP53 expression,
including enlarged nuclei compared with the others in the study
(Fig 1A, plate 6), highlighting it for further analysis (see below).
No detectable TP53 expression was noted in 12 normal vulvar
and three nongenital normal epithelium specimens.
To initiate our investigation into the status of the TP53
expressed in LS samples we examined the expression of p21/
WAF-1/CIP-1, a TP53 responsive gene. In two cases a clear
relationship between the two genes expression was evident
(Fig 1B) where the basal cell and epidermal expression
coincided. Although, p21 expression extended beyond the basal
layer in these examples (perhaps due to longer p21 half life
compared with TP53), in general p21 expression in the basal
layer of LS was uncommon and rarely were TP53 and p21 found
in the same cells. Others have observed such discordant
expression in normal and malignant tissues and most notably in
mouse cells where both alleles of the p53 gene had been deleted
(el-Deiry et al, 1995). This suggested to us that the expression
status of p21 is by itself unhelpful in determining whether the
observed TP53 is a wild-type or mutant protein.
There was no evidence that TP53 expression increased from
nongenital LS to LS of the vulva without VC to LS adjacent to
VC (p¼ 0.52) when all cases were included in the analysis. It
should be noted, however, that only 48% of cases of LS found
adjacent toVC exhibited anyTP53 expression perhaps leading to
a potential skewing of the distribution of the data (Fig 2A). As
p53 mutation can lead to the complete absence of detectable
expression and absence of TP53 can be simply a function of
failed antigen retrieval, we also examined these groups
following the exclusion of all completely negative cases. That is,
cases where not a single nucleus within three ¢elds stained
positive for TP53 antigen. Consequently, 15 (52%) cases of LS
found adjacent to VC and one (3%) case of nongenital LS were
omitted from the analysis. Using these sampling criteria, there
was strong evidence that TP53 expression increased from
nongenital LS to LS of the vulva without VC to LS found
adjacent toVC (po0.0001, Fig 2B).
The intensity of TP53 expression was also documented in the
VC cases and their adjacent epithelium (Table IA). There was an
increasing linear trend in intensity of TP53 expression from
adjacent normal tissue to tissue with LS only to LS coexistent
with SCH or DVIN to the tumor (po0.0001).
A comparison of intensity between all groups of LS was
performed (Table IB). Both groups of nongenital LS and LS
without VC had no evidence of SCH or DVIN. Hence, in the
group of LS adjacent to VC, the 25 cases with no evidence of
SCH or DVIN were included for the comparison. Although
there was a trend to more intense TP53 staining from
nongenital LS to LS of the vulva with VC to LS adjacent to VC
the di¡erence based upon the sample size was not signi¢cantly
di¡erent (p¼ 0.24).
Figure1. (A) Panels 1 and 2: TP53 expression detected by immuno-
histochemistry in two cases of LS adjacent to tumor demonstrating
focal patches of TP53 expression indicated by arrows (cases 8VC
and 22VC). Panel 3: aVC (case 18VC) with extensive TP53 staining. Panels
4 and 5: showTP53 expression in LS of the vulvar without cancer case 4LS
and with nongenital LS, case 18LS. Panel 6: Case 30LS had marked TP53
protein expression and enlarged nuclei compared with other LS cases. (B)
Panels 1^4: LS cases 4LS and 10LS showing (arrows) p21 staining corresponds
to regions of TP53 detection in the basal layer, although p21 expression
extends into the epidermis beyond where TP53 staining is detectable. Ori-
ginal magni¢cation 200.
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LOH p53 LOH was assessed using two polymorphic markers,
where 19 of 29 were informative for at least one of the two
polymorphic loci. Fourteen of 19 VC had LOH, where LOH
was also detected in the adjacent components; ¢ve LS, and ¢ve
LS superimposed with either SCH or DVIN (Fig 3). No LOH
was detected in LS without VC, and nongenital LS, where 28 of
37 and eight of 10, respectively, were informative for at least one
of the two polymorphic loci tested. Therefore, the LOH analysis
suggested allelic loss of the p53 gene in VC and its adjacent
components.
p53 mutations DNA sequence analysis of the p53 gene in all
VC cases and adjacent components focused upon the frequently
reported hotspot regions, exons 5^8. In nine of 29 VC cases p53
mutations were observed in either the tumor, adjacent LS or in
both (Table II). Eight tumors had a detectable p53 mutation. An
example of a p53 mutation in a VC case is shown in Fig 4(A)
and, importantly, the presence of the same p53 mutation in LS
and VC from the same patient that is absent in the normal tissue
(Fig 4B).Table II combines the three data sets highlighting the
lack of association of LOH and p53 mutations in the presence of
high TP53 expression in LS and VC. On a technical note we
found that our initial set of mutational data revealed that
approximately 49% of VC have p53 mutation; however, in some
instances further replicate experiments failed to reproduce the
original documented mutation. Di⁄culties in processing and
sequencing para⁄n-derived DNA is notorious for p53 mutation
detection (Williams et al, 1999) leading to false positive
determinations. The reports of p53 mutations made here are
based upon triplicates derived from three independent PCR.
The consistency and accuracy of our direct sequencing
techniques and the integrity of our DNAwas supported by the
continual reproducibility (triplicate independent PCR) of
amino acid codon polymorphisms in the VC and adjacent
epithelial lesions, and the absolute reproducibility of a docu-
mented p53 mutation (40 of 40 cloned and sequenced products
following PCR) from aVC cell line, A431 (data not shown).
Figure 2. The number of TP53 positive cells assessed per 100 basal
cells is shown for nongenital LS, LS of the vulvar without carcino-
ma, and LS adjacent to carcinoma. (A) Analysis includes the whole
data set. (B) Data set excluding all totally negative (0% staining) TP53 cases
on the basis that TP53 expression may be lost due to genomic loss and/or
failed antigen retrieval.
Table I. (A) IntensityTP53 staining inVC and adjacent tissues
Tissue Total no.
of cases
Cases with a
score of at least 2
or more
Normal 14 1 (7%)
LS 25 5 (20%)
LS coexistent with
SCH or DVIN
9 2 (22%)
Tumor 29 15 (52%)
(B) Comparison of intensity of TP53 staining between
all groups of LS
Type Total no.
of cases
No. of cases
with a score
of at least 2
Non-genital LS 10 0
LS of the vulva without VC 37 9 (24%)
LS adjacent toVC 25 5 (20%)
Figure 4. Two cases with p53 mutations detected by direct sequen-
cing are shown. (A) p53 exon 5 mutation detected in tumor (T) but not
in matched normal tissue from case 19VC, and (B) an identical mutation
found in tumor (T) and adjacent LS in case 10VC.
Figure 3. (A,B) LOH analysis of a polymorphic marker (AAAAT)8
repeat mapped to chromosome 17p showing loss of the upper allele
in normal (N), LS, SCH, tumor (T) in case 24VC, and LOH of the
lower allele in LS and T in case 9VC. (C) LOH at the (CA)25 repeat of
the upper allele in LS coexistent with DVIN, and tumor (T) in case 8VC.
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Three cases had a detectable mutation in adjacent LS, two of
which had matching mutations in the tumor. This association is
highly statistically signi¢cant (p¼ 0.007), whereas the remaining
case had a mutation detected only in LS.The matching mutations
in LS and the tumor are important for two reasons: these were
the ¢rst reported cases of p53 mutations in LS and they suggest
that the epithelial tumor cells arose from the same clone of cells
with LS.
We did not detect p53 mutations in LS without VC even in
one candidate case with markedly intense TP53 expression and
aberrant nuclear morphology (Fig 1A, panel 6). Furthermore, in
all cases direct sequencing identi¢ed wild-type and mutant alleles
present at the site of mutation suggesting that the wild-type allele
had not been lost. These data suggest that selection for
homozygous loss of the wild-type p53 is not a requisite for VC
or perhaps that selection for LOH of another chromosome p17
locus underlies the apparent uncoupling of the LOH and
mutation data.
DISCUSSION
The incidence of p53 mutations in late stage epithelial cancers
is typically reported to be 50^70% (Hollstein et al, 1991). This
study has focused upon the possible role of p53 in early events
in VC initiation and progression. The relationship between
early onset VC and HPV infection implicates TP53 inactivation
as an early event in this group of VC patients. Similarly, the
frequent association betweenVC and the dermatologic condition
LS in HPV-negative VC patients has led to the suggestion of a
parallel role for p53 mutations in LS progression to VC. This
study examined the p53 status of VC in the context of adjacent
LS and found p53 mutations in VC can be observed in adjacent
LS. p53 mutations and LOH, however, could not account for
the high apparently wild-type TP53 expression observed in LS
of the vulva.
The importance of HPV in tumor development became appar-
ent from studies investigating the pathogenesis of cervical carci-
noma. HPV 16 and 18 are most commonly found in cervical
carcinoma (Vousden, 1989) and virally encoded E6 forms a com-
plex with TP53 (Werness et al, 1990). HPV-positive cervical carci-
nomas rarely show p53 mutations (Fujita et al, 1992; Kessis et al,
1993). This led to the subsequent revelation that loss of wild-type
p53 is important in the pathogenesis of HPV-negative cervical
carcinoma. In the absence of HPV, tumor development is said
to be reliant upon the loss of TP53 function through somatic
mutations (Crook et al, 1991, 1992). Indeed, mutations in the
p53 gene have been reported in HPV-negative VC as they have
been in numerous other human cancers (Hollstein et al, 1991;
Greenblatt et al, 1994).
Detection of mutant TP53 has been widely investigated in
using immunohistochemistry on the basis that it is more stable
Table II. Combined data showing TP53 immunohistochemistry, p53 LOH and mutation analysis of VC and adjacent LS
TP53 immunohistochemistry Histologic location of LOH p53 mutation analysis
# Negative Tumor
Positive
Tumor &
Adjacent
Components
Positive
LOH
Overall
Adjacent
Components
Tumor Tumor &
Adjacent
Components
Positive
Site Codon/Amino Acid Change Mutation
Plus
LOH
1 þ NI
2 þ LOH ca
3 þ LOH ca
4 þ In
6 þ NI
7 þ In LS 193 CAT-4GAT His4Asp
T 193 CAT-4GAT His4Asp
8 þ LOH aaaat ca
9 þ LOH aaaat
10 þ LOH aaaat LS 248 CGG-4CAG Arg4Gln X
T 248 CGG-4CAG Arg4Gln
11 þ LOH aaaat
12 þ LOH aaaat T 248 CGG-4CAG Arg4Gln X
13 þ LOH ca aaaat
14 þ LOH ca
15 þ I T 193 CAT-4GAT His4Asp
16 þ LOH aaaat
17 þ NI
18 þ LOH aaaat/ca
19 þ In T 157 GTC-4TTC Val4Phe
20 þ NI
21 þ LOH aaaat
22 þ NI
23 þ NI
24 þ LOH LS: ca aaaat T 158 CGC-4CAC Arg4His X
159 GCC-4GGC Ala4Gly
25 þ In
26 þ NI T 248 CGG-4CAG Arg4Gln
27 þ LOH aaaat LS 167 CAG-4CGG Gln4Arg X
28 þ NI
30 þ NI T 207 GAT-4AAT Asp4Asn
31 þ NI
Mutation analysis based upon 3 separate PCR and sequencing reactions. ca and aaaat refer to polymorphic repeats.
ninformative at both polymorphic markers
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and abundant than the wild-type protein; however, immunohis-
tochemistry employing many of the anti-TP53 reagents do not
discriminate between wild-type and mutant forms of TP53 (Bat-
tifora, 1994), thus there is a need for caution when interpreting
results. Expression of TP53 is minimal in most normal cells
(MacGeoch et al, 1993; Battifora, 1994), including cells of normal
vulvar skin (Soini et al, 1994; Kagie et al, 1997; McConnell et al,
1997) and normal nongenital skin samples examined here.When
we considered only cases where we were certain TP53 antigen
retrieval was successful, we found a marked di¡erence in
TP53 expression between nongenital LS compared with vulvar
LS (po0.0001). This suggests that the di¡erent anatomical loca-
tion of LS has consequences relevant to tumor development
(McConnell et al, 1997).
TP53 expression arises when it is serving as the central media-
tor of the G1/S checkpoint in response to DNA damage (Leonard
et al, 1995) and detectable TP53 expression was found in 97% of
nongenital LS cases and in some cases a substantial proportion of
cells expressedTP53.Therefore, although, LS is considered to be a
non-neoplastic disease these results suggest that the accumulation
of TP53 in LS in the absence of carcinoma is due to the overex-
pression of wild-type TP53. Thus wild-type TP53 overexpression
may be a feature of this in£ammatory disease (Soini et al, 1994;
Tan et al, 1994). Others have recently reported that another com-
ponent of the p53 pathway, mdm2, may be in£uencing wild-type
TP53 expression (Carlson et al, 2001); however, we favor the view
that the TP53 expression we have observed re£ects a stress re-
sponse associated with in£ammation or carcinogenic insult and
perhaps cell cycle arrest. In support of this view is an increase in
expression in LS of the TP53-target gene p21 (in some LS cases)
the expression of which is associated with arrest; however, our
data did not show a tight concordance between p21 and TP53 ex-
pression in all cases of LS or VC attesting to the complex nature
of p21 regulation in normal and malignant tissues (el-Deiry et al,
1995). Therefore, our ¢nding of TP53 expression in 72% VC
cases was vastly in excess of the detection of p53 mutation. A
similar situation has been reported where adjacent ‘‘normal’’ epi-
dermis and basal cell carcinoma showed considerable divergence
between TP53 expression and detectable p53 mutation (Ponten
et al, 1997).
The use of DNA microsatellites as markers of LOH on chro-
mosome 17 has been investigated extensively in a variety of hu-
man tumors, including squamous cell carcinomas of the skin,
where approximately 33% of squamous cell carcinomas have al-
lelic loss of chromosome 17p (Quinn et al, 1994). Seventy-four
percent of VC cases informative for at least one of the two poly-
morphic loci had LOH at either p53 loci tested. In another study
four of ¢ve of HPV-negative VC had LOH at chromosome 17p
(Pinto et al, 1999). To the best of knowledge our study is the ¢rst
to demonstrate LOH in the VC precursor lesion LS.We detected
nine cases of LS adjacent to VC with LOH. Very importantly,
LOH was not detected in LS of the cancer-free vulvar or in
nongenital LS, at best supporting the role of p53 loss as a mid
(Carlson et al., 2001) to late event in vulvar cancer progression.
Our ¢nding that VC cases had an identical p53 mutation in the
adjacent LS for the ¢rst time shows molecular evidence for the
progression from this condition to cancer. Although these data
do not prove that LS progressed toVC, the association of an iden-
tical mutation in matching LS andVC from the same patient was
highly signi¢cant (p¼ 0.007) and, therefore, it is extremely
unlikely that in these two cases, the VC did not arise from the
adjacent LS.
Our ¢nding that LOH did not predict the presence of a muta-
tion in p53 is in opposition to the traditional view that p53 muta-
tion is frequently followed by the loss of the wild-type allele.
There are two explanations for a lack of p53 mutations within
these tumors: (i) mutations being harbored outside the sequences
tested, and (ii) the loss of another gene on chromosome 17p as
observed in other cancers (Chen et al, 1991; Cornelis et al, 1994;
Swift et al, 1995; Grebe et al, 1997). Therefore we argue that p53
mutations arise at a later stage inVC development rather than act-
ing as the driving force underlying vulvar carcinogenesis. The
data are also most consistent with the loss of a tumor suppressor
gene on chromosome 17p as an early event in the development of
VC from LS. In circumstances where LOH and p53 mutations are
clearly associated and very likely to be of etiologic importance the
detection of p53 mutation precedes the apparent selection of
LOH (Greenblatt et al, 1994; May et al, 1999). Contrasting this sce-
nario is the appearance of chromosome 17p LOH in LS before the
emergence of p53 mutations in VC coupled to the observation
that LOH of the mutant allele was commonly observed. This
study presents evidence for chromosome 17p LOH in a premalig-
nant dermatologic disease associated with this form of squamous
cell carcinoma. This suggests an alternative pathway to that ori-
ginally implicated by molecular studies based upon early onset
HPV-positive VC.
We thank Dr Richard Fisher of the Statistical Center (PMCI) for his advice on data
analysis. A Mercy Hospital Research grant and a National Health and Medical Re-
search Council Senior Research Fellowship to RR supported this study.
REFERENCES
Battifora H: p53 immunohistochemistry: a word of caution. Hum Pathol 25:435^437,
1994
Brash DE, Rudolph JA, Simon JA, et al: A role for sunlight in skin cancer: UV-in-
duced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA
88:10124^10128, 1991
Carlson JA, Ambros R, Malfetano J, et al: Vulvar lichen sclerosus and squamous cell
carcinoma: a cohort, case control, and investigational study with historical per-
spective; implications for chronic in£ammation and sclerosis in the develop-
ment of neoplasia. Hum Pathol 29:932^948, 1998
Carlson JA, Amin S, Malfetano J, et al: Concordant p53 and mdm-2 protein expres-
sion in vulvar squamous cell carcinoma and adjacent lichen sclerosus. Appl
Immunohistochem Mol Morphol 9:150^163, 2001
Cawkwell L, Lewis FA, Quirke P: Frequency of allele loss of DCC, p53, RBI,WT1,
NF1, NM23 and APC/MCC in colorectal cancer assayed by £uorescent multi-
plex polymerase chain reaction. Br J Cancer 70:813^818, 1994
Chen LC, Neubauer A, KurisuW, et al: Loss of heterozygosity on the short arm of
chromosome 17 is associated with high proliferative capacity and DNA aneu-
ploidy in primary human breast cancer. Proc Natl Acad Sci USA 88:3847^3851,
1991
Collett D: Modelling Binary Data. Chapman and Hill, London, UK, 1991
Cornelis RS, van Vliet M, Vos CB, et al: Evidence for a gene on 17p13.3, distal to
TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer
Res 54:4200^4206, 1994
CrookT,Wrede D,Vousden KH: p53 point mutation in HPV negative human cervi-
cal carcinoma cell lines. Oncogene 6:873^875, 1991
Crook T,Wrede D,Tidy JA, MasonWP, Evans DJ,Vousden KH: Clonal p53 muta-
tion in primary cervical cancer: association with human-papillomavirus-nega-
tive tumours. Lancet 339:1070^1073, 1992
el-DeiryWS,Tokino T,Waldman T, et al: Topological control of p21WAF1/CIP1 ex-
pression in normal and neoplastic tissues. Cancer Res 55:2910^2919, 1995
Fujita M, Inoue M,Tanizawa O, Iwamoto S, EnomotoT: Alterations of the p53 gene
in human primary cervical carcinoma with and without human papilloma-
virus infection. Cancer Res 52:5323^5328, 1992
Grebe SK, McIver B, Hay ID, et al: Frequent loss of heterozygosity on chromosomes
3p and 17p without VHL or p53 mutations suggests involvement of unidenti-
¢ed tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol
Metab 82:3684^3691, 1997
Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor
suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer
Res 54:4855^4878, 1994
Helland A, Holm R, Kristensen G, et al: Genetic alterations of the TP53 gene, p53
protein expression and HPV infection in primary cervical carcinomas. J Pathol
171:105^114, 1993
Hollstein M, Sidransky D,Vogelstein B, Harris CC: p53 mutations in human cancers.
Science 253:49^53, 1991
Hording U, Junge J, Daugaard S, Lundvall F, Poulsen H, Bock JE: Vulvar squamous
cell carcinoma and papillomaviruses: indications for two di¡erent etiologies.
Gynecol Oncol 52:241^246, 1994
Jones MH, Nakamura Y: Detection of loss of heterozygosity at the human TP53
locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 5:
89^90, 1992
Kagie MJ, Kenter GG,Tollenaar RA, Hermans J,Trimbos JP, Fleuren GJ: p53 protein
over-expression, a frequent observation in squamous cell carcinoma of the vulva
1032 VANIN ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
and in various synchronous vulvar epithelia, has no value as a prognostic para-
meter. Int J Gynecol Pathol 16:124^130, 1997
Kessis TD, Slebos RJ, Han SM, et al: p53 gene mutations and MDM2 ampli¢cation
are uncommon in primary carcinomas of the uterine cervix. Am J Pathol
143:1398^1405, 1993
KimYT,Thomas NF, Kessis TD,Wilkinson EJ, Hedrick L, Cho KR: p53 mutations
and clonality in vulvar carcinomas and squamous hyperplasias: evidence sug-
gesting that squamous hyperplasias do not serve as direct precursors of human
papillomavirus-negative vulvar carcinomas. Hum Pathol 27:389^395, 1996
LeeYY,Wilczynski SP, ChumakovA, Chih D, Koe¥er HP: Carcinoma of the vulva:
HPV and p53 mutations. Oncogene 9:1655^1659, 1994
Leibowitch M, Neill S, Pelisse M, Moyal-Baracco M: The epithelial changes asso-
ciated with squamous cell carcinoma of the vulva: a review of the clinical, his-
tological and viral ¢ndings in 78 women. Br J Obstet Gynaecol 97:1135^1139, 1990
Leonard CJ, Canman CE, Kastan MB: The role of p53 in cell-cycle control and
apoptosis: implications for cancer. Important Adv Oncol 33^42, 1995
MacGeoch C, Barnes DM, Newton JA, et al: p53 protein detected by immunohisto-
chemical staining is not always mutant. Dis Markers 11:239^250, 1993
May P, May E:Twenty years of p53 research: structural and functional aspects of the
p53 protein. Oncogene 18:7621^7636, 1999
McConnell DT, Miller ID, Parkin DE, Murray GI: p53 protein expression in a
population-based series of primary vulval squamous cell carcinoma and
immediate adjacent ¢eld change. Gynecol Oncol 67:248^254, 1997
Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T:
Presence and persistence of HPV infection and p53 mutation in cancer of the
cervix uteri and the vulva. Int J Cancer 63:639^645, 1995
Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koe¥er HP: p53 mutations in
HPV-negative cervical carcinoma. Oncogene 9:205^210, 1994
Pilotti S, D’Amato L, DellaTorre G, et al: Papillomavirus, p53 alteration, and primary
carcinoma of the vulva. Diagn Mol Pathol 4:239^248, 1995
Pinto AP, Lin MC, Mutter GL, Sun D, Villa LL, Crum CP: Allelic loss in human
papillomavirus-positive and -negative vulvar squamous cell carcinomas. Am J
Pathol 154:1009^15, 1999
Ponten F, Berg C, Ahmadian A, et al: Molecular pathology in basal cell cancer with
p53 as a genetic marker. Oncogene 15:1059^67, 1997
Pride HB, Miller OFD, Tyler WB: Penile squamous cell carcinoma arising from
balanitis xerotica obliterans. J Am Acad Dermatol 29:469^473, 1993
Quinn AG, Sikkink S, Rees JL: Basal cell carcinomas and squamous cell carcinomas
of human skin show distinct patterns of chromosome loss. Cancer Res 54:
4756^4759, 1994
Ridley CM:The aetiology of vulval neoplasia. Br J Obstet Gynaecol 101:655^657, 1994
Scurry J, Vanin K, Ostors A: Comparison of histological features of vulvar lichen
sclerosis with and without adjacent squamous cell carcinoma. Int J Gynecol Can-
cer 7:392^399, 1997
Scurry J, Flowers L,Wistuba I, Vanin K, Mulvany N, Reyes N, Gazdar A: Human
papillomavirus, lichen sclerosis and vulvar squamous cell carcinoma. Int J
Gynecol Cancer 8:298^306, 1998
Sliutz G, Schmidt W,Tempfer C, et al: Detection of p53 point mutations in primary
human vulvar cancer by PCR and temperature gradient gel electrophoresis.
Gynecol Oncol 64:93^98, 1997
Soini Y, Paakko P,Vahakangas K,Vuopala S, Lehto VP: Expression of p53 and pro-
liferating cell nuclear antigen in lichen sclerosus et atrophicus with di¡erent
histological features. Int J Gynecol Pathol 13:199^204, 1994
Swift A, Risk JM, Kingsnorth AN,Wright TA, Myskow M, Field JK: Frequent loss
of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett’s adenocarcino-
ma. Br J Cancer 71:995^998, 1995
Tan SH, Derrick E, McKee PH, Hobbs C, Ridley M, Neill S: Altered p53 expression
and epidermal cell proliferation is seen in vulval lichen sclerosus. J Cutan Pathol
21:316^323, 1994
Thomas M, Pim D, Banks L: The role of the E6^p53 interaction in the molecular
pathogenesis of HPV. Oncogene 18:7690^7700, 1999
Toki T, Kurman RJ, Park JS, Kessis T, Daniel RW, Shah KV: Probable nonpapilloma-
virus etiology of squamous cell carcinoma of the vulva in older women: a clin-
icopathologic study using in situ hybridization and polymerase chain reaction.
Int J Gynecol Pathol 10:107^125, 1991
Vousden KH: Human papillomaviruses and cervical carcinoma. Cancer Cells 1:43^50,
1989
Weber P, Rabinovitz H, Garland L:Verrucous carcinoma in penile lichen sclerosus et
atrophicus. J Dermatol Surg Oncol 13:529^532, 1987
Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16
and 18, E6 proteins with p53. Science 248:76^79, 1990
Williams C, Ponten F, Moberg C, et al: A high frequency of sequence alterations
is due to formalin ¢xation of archival specimens. Am J Pathol 155:1467^1471,
1999
P53 EXPRESSION IN LICHEN SCLEROSUS AND VULVARCARCINOMA 1033VOL. 119, NO. 5 NOVEMBER 2002
